住院癌症患者重型皮肤不良反应全身受累与死亡标志物研究
回顾性分析49例住院癌症伴麻疹样皮疹且已行皮肤科会诊的患者,分为无全身受累的单纯型与伴全身受累的复杂型。皮肤科会诊后6个月内15例(30.6%)死亡;死亡者弹力素、IL-6、TNF-α显著高于存活者,药物相关复杂皮疹者IL-6、IL-10显著升高。
要点
- 会诊后6个月内死亡15/49例(30.6%)。
- 死亡患者弹力素、IL-6、TNF-α显著高于6个月存活者。
- 药物相关复杂皮疹患者IL-6、IL-10显著升高。
核心结论
- 在癌症合并重型皮肤不良反应患者中,弹力素、IL-6、TNF-α水平可能预测不良结局。
- 针对这些靶点的药物可能是预防致命性重型皮肤不良反应的合理治疗方向。
研究设计与样本
- 回顾性研究,纳入49例住院癌症伴麻疹样皮疹、记录血清细胞因子(IL-6、IL-10、TNF-α)或弹力素检测、且既往有皮肤科会诊的患者。
- 患者分为无全身受累的单纯麻疹样皮疹与伴全身受累的复杂麻疹样皮疹两类。
主要发现
- 49例中15例(30.6%)在皮肤科会诊后6个月时死亡。
- 死亡患者弹力素、IL-6、TNF-α显著高于6个月时仍存活患者。
- 药物相关复杂皮疹患者IL-6、IL-10显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性设计。
- 样本量有限。
- 患者人群为高危人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe cutaneous adverse reactions (SCARs) are frequent in inpatient oncology. Early intervention might reduce morbidity, mortality, and hospitalization costs; however, current clinical and histologic features are unreliable SCAR predictors. There is a need to identify rational markers of SCARs that could lead to effective therapeutic interventions. OBJECTIVE: To characterize the clinical and serologic features of hospitalized patients with cancer who developed SCARs. METHODS: Retrospective review of 49 hospitalized cancer patients with a morbilliform rash, recorded testing for serum cytokines (interleukin [IL] 6, IL-10, and tumor necrosis factor [TNF] α) or elafin, and a prior dermatology consultation. Patients were categorized as having a simple morbilliform rash without systemic involvement or complex morbilliform rash with systemic involvement. RESULTS: Fifteen out of 49 patients (30.6%) were deceased at 6 months from time of dermatologic consultation. Elafin, IL-6, and TNF-α were significantly higher in patients who died compared with patients who were still alive at 6 months. IL-6 and IL-10 were significantly higher in patients with a drug-related complex rash. LIMITATIONS: Retrospective design, limited sample size, and high-risk patient population. CONCLUSION: In cancer patients with SCARs, elafin, IL-6, and TNF-α levels might predict a poor outcome. Agents directed against these targets might represent rational treatments for the prevention of fatal SCARs.
引用
- Mori S, Hickey A, Dusza SW, et al. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. J Am Acad Dermatol. 2018. PMID: 30612984. doi:10.1016/j.jaad.2018.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。